{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:47:44Z","timestamp":1762854464195,"version":"build-2065373602"},"reference-count":66,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.gofs.2023.03.001","type":"journal-article","created":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T22:30:33Z","timestamp":1678833033000},"page":"275-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Femmes \u00e0 tr\u00e8s haut risque de cancer du sein\u00a0: contraception, traitement hormonal substitutif et d\u00e9pistage personnalis\u00e9"],"prefix":"10.1016","volume":"51","author":[{"given":"C.","family":"Duffau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Weyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gosset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Tremolli\u00e8res","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Vaysse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Dalenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2014","series-title":"Recommandations de sant\u00e9 publique\u00a0: \u00ab\u00a0D\u00e9pistage du cancer du sein en France\u00a0: identification des femmes \u00e0 haut risque et modalit\u00e9s de d\u00e9pistage\u00a0\u00bb","key":"10.1016\/j.gofs.2023.03.001_bib0335"},{"key":"10.1016\/j.gofs.2023.03.001_bib0340","first-page":"372","article-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990\u00a0et 2018","volume":"1","author":"Defossez","year":"2019","journal-title":"Tumeurs solides"},{"issue":"2","key":"10.1016\/j.gofs.2023.03.001_bib0345","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.ygyno.2019.01.027","article-title":"Large-scale meta-analysis of mutations identified in panels of breast\/ovarian cancer-related genes\u00a0\u2014\u00a0Providing evidence of cancer predisposition genes","volume":"153","author":"Suszynska","year":"2019","journal-title":"Gynecol Oncol"},{"year":"2017","series-title":"Femmes porteuses d\u2019une mutation de BRCA1\u00a0ou BRCA2\/D\u00e9tection pr\u00e9coce du cancer du sein et des annexes et strat\u00e9gies de r\u00e9duction du risque, Collection recommandations et r\u00e9f\u00e9rentiels","key":"10.1016\/j.gofs.2023.03.001_bib0350"},{"year":"2020","series-title":"Oncog\u00e9n\u00e9tique en 2018\/consultations, laboratoires et suivi (2017\u00a0et 2018)","key":"10.1016\/j.gofs.2023.03.001_bib0355"},{"issue":"1","key":"10.1016\/j.gofs.2023.03.001_bib0360","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1\u00a0and BRCA2\u00a0mutation carriers: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5","key":"10.1016\/j.gofs.2023.03.001_bib0365","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1\u00a0or BRCA2\u00a0mutations detected in case series unselected for family history: a combined analysis of 22\u00a0studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"1","key":"10.1016\/j.gofs.2023.03.001_bib0370","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2018.05.011","article-title":"Age-specific ovarian cancer risks among women with a BRCA1\u00a0or BRCA2\u00a0mutation","volume":"150","author":"Kotsopoulos","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2023.03.001_bib0375","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.patbio.2006.02.002","article-title":"Identification et prise en charge des pr\u00e9dispositions h\u00e9r\u00e9ditaires aux cancers du sein et de l\u2019ovaire (mise \u00e0 jour 2004)","volume":"54","author":"Eisinger","year":"2006","journal-title":"Pathol Biol"},{"issue":"2","key":"10.1016\/j.gofs.2023.03.001_bib0380","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.suronc.2015.04.003","article-title":"Gene analysis techniques and susceptibility gene discovery in non-BRCA1\/BRCA2\u00a0familial breast cancer","volume":"24","author":"Aloraifi","year":"2015","journal-title":"Surg Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2023.03.001_bib0385","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa1400382","article-title":"Breast-cancer risk in families with mutations in PALB2","volume":"371","author":"Antoniou","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gofs.2023.03.001_bib0390","unstructured":"Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, et al. Li-fraumeni and related syndromes: correlation between tumor type, family structure, and TP53\u00a0genotype. Cancer Res 9."},{"issue":"23","key":"10.1016\/j.gofs.2023.03.001_bib0395","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/cncr.30248","article-title":"Risks of first and subsequent cancers among TP53\u00a0mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort: cancer risk in TP53\u00a0mutation carriers","volume":"122","author":"Mai","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2023.03.001_bib0400","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jamaoncol.2014.168","article-title":"Hereditary diffuse gastric cancer syndrome: CDH1\u00a0mutations and beyond","volume":"1","author":"Hansford","year":"2015","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.gofs.2023.03.001_bib0405","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1078-0432.CCR-11-2283","article-title":"Lifetime cancer risks in individuals with germline PTEN mutations","volume":"18","author":"Tan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.gofs.2023.03.001_bib0410","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.bulcan.2018.08.003","article-title":"Recommandations fran\u00e7aises du Groupe G\u00e9n\u00e9tique et Cancer pour l\u2019analyse en panel de g\u00e8nes dans les pr\u00e9dispositions h\u00e9r\u00e9ditaires au cancer du sein ou de l\u2019ovaire","volume":"105","author":"Moretta","year":"2018","journal-title":"Bull Cancer (Paris)"},{"issue":"22","key":"10.1016\/j.gofs.2023.03.001_bib0415","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.3390\/cancers13225654","article-title":"Oral contraceptive use and breast cancer risk assessment: a systematic review and meta-analysis of case-control studies, 2009\u20132020","volume":"13","author":"Bara\u0144ska","year":"2021","journal-title":"Cancers"},{"issue":"9017","key":"10.1016\/j.gofs.2023.03.001_bib0420","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(96)90806-5","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297\u00a0women with breast cancer and 100 239\u00a0women without breast cancer from 54\u00a0epidemiological studies","volume":"347","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1996","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.gofs.2023.03.001_bib0425","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1016\/j.ejca.2010.04.018","article-title":"Oral contraceptive use and breast or ovarian cancer risk in BRCA1\/2\u00a0carriers: a meta-analysis","volume":"46","author":"Iodice","year":"2010","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.gofs.2023.03.001_bib0430","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1586\/era.11.38","article-title":"Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis","volume":"11","author":"Cibula","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"issue":"33","key":"10.1016\/j.gofs.2023.03.001_bib0435","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","article-title":"Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis","volume":"31","author":"Moorman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2023.03.001_bib0440","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10549-013-2823-4","article-title":"Timing of oral contraceptive use and the risk of breast cancer in BRCA1\u00a0mutation carriers","volume":"143","author":"Kotsopoulos","year":"2014","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.gofs.2023.03.001_bib0445","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.18632\/oncotarget.13423","article-title":"The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation","volume":"8","author":"Toss","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.gofs.2023.03.001_bib0450","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/j.clbc.2017.10.016","article-title":"Combined hormonal contraceptive use and risk of breast cancer in a population of women with a family history","volume":"18","author":"Grandi","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"9609","key":"10.1016\/j.gofs.2023.03.001_bib0455","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45\u00a0epidemiological studies including 23,257\u00a0women with ovarian cancer and 87,303\u00a0controls","volume":"371","author":"Collaborative Group on Epidemiological Studies of Ovarian Cancer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.gofs.2023.03.001_bib0460","unstructured":"Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish women's lifestyle and health cohort study 8."},{"issue":"6","key":"10.1016\/j.gofs.2023.03.001_bib0465","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/ijc.11167","article-title":"Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study","volume":"105","author":"Dumeaux","year":"2003","journal-title":"Int J Cancer"},{"issue":"23","key":"10.1016\/j.gofs.2023.03.001_bib0470","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1056\/NEJMoa1700732","article-title":"Contemporary hormonal contraception and the risk of breast cancer","volume":"377","author":"M\u00f8rch","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gofs.2023.03.001_bib0475","doi-asserted-by":"crossref","first-page":"100470","DOI":"10.1016\/j.lanepe.2022.100470","article-title":"Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15-34\u00a0years of age: A nationwide register-based study","volume":"21","author":"Niemeyer Hultstrand","year":"2022","journal-title":"Lancet Reg Health Eur"},{"issue":"12","key":"10.1016\/j.gofs.2023.03.001_bib0480","first-page":"2197","article-title":"Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancer","volume":"24","author":"Faber","year":"2013","journal-title":"Cancer Causes Control"},{"issue":"5","key":"10.1016\/j.gofs.2023.03.001_bib0485","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.contraception.2003.12.015","article-title":"Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer","volume":"69","author":"Strom","year":"2004","journal-title":"Contraception"},{"issue":"11","key":"10.1016\/j.gofs.2023.03.001_bib0490","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/ijc.22970","article-title":"Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non-Hispanic white women","volume":"121","author":"Sweeney","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.gofs.2023.03.001_bib0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2022.01.014","article-title":"Contraceptive use and the risk of ovarian cancer among women with a BRCA1\u00a0or BRCA2\u00a0mutation","author":"Xia","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.gofs.2023.03.001_bib0500","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/aogs.13817","article-title":"Levonorgestrel-releasing intrauterine system and breast cancer risk: a systematic review and meta-analysis","volume":"99","author":"Conz","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"10.1016\/j.gofs.2023.03.001_bib0505","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2018.02.006","article-title":"Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study","volume":"149","author":"Jareid","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.gofs.2023.03.001_bib0510","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.clbc.2021.03.013","article-title":"Meta-analysis of breast cancer risk in levonorgestrel-releasing intrauterine system users","volume":"21","author":"Silva","year":"2021","journal-title":"Clin Breast Cancer"},{"issue":"2\u00a0Pt 1","key":"10.1016\/j.gofs.2023.03.001_bib0515","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/AOG.0000000000000356","article-title":"Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland","volume":"124","author":"Soini","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.gofs.2023.03.001_bib0520","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.bjc.6603618","article-title":"Oral progestagens before menopause and breast cancer risk","volume":"96","author":"Fabre","year":"2007","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.gofs.2023.03.001_bib0525","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1158\/1055-9965.EPI-08-0056","article-title":"Progestagens use before menopause and breast cancer risk according to histology and hormone receptors","volume":"17","author":"Fabre","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.gofs.2023.03.001_bib0530","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/jnci\/djn442","article-title":"Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1\u00a0or BRCA2\u00a0mutation carriers","volume":"101","author":"Rebbeck","year":"2009","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.gofs.2023.03.001_bib0535","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12905-014-0150-5","article-title":"Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1\u00a0and BRCA 2\u00a0mutation carriers","volume":"14","author":"Marchetti","year":"2014","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.gofs.2023.03.001_bib0540","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psyneuen.2019.03.013","article-title":"Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta-analysis","volume":"106","author":"Georgakis","year":"2019","journal-title":"Psychoneuroendocrinology"},{"issue":"11","key":"10.1016\/j.gofs.2023.03.001_bib0545","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.mayocp.2016.08.002","article-title":"Accelerated accumulation of multimorbidity after bilateral oophorectomy: a population-based cohort study","volume":"91","author":"Rocca","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"10.1016\/j.gofs.2023.03.001_bib0550","doi-asserted-by":"crossref","first-page":"e198420","DOI":"10.1001\/jamanetworkopen.2019.8420","article-title":"Changes in bone mineral density after prophylactic bilateral salpingo-oophorectomy in carriers of a BRCA mutation","volume":"2","author":"Kotsopoulos","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.gofs.2023.03.001_bib0555","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10689-011-9480-8","article-title":"Non-cancer endpoints in BRCA1\/2\u00a0carriers after risk-reducing salpingo-oophorectomy","volume":"11","author":"Cohen","year":"2012","journal-title":"Fam Cancer"},{"issue":"24","key":"10.1016\/j.gofs.2023.03.001_bib0560","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1001\/jama.2019.19191","article-title":"Association of premature natural and surgical menopause with incident cardiovascular disease","volume":"322","author":"Honigberg","year":"2019","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.gofs.2023.03.001_bib0565","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/AOG.0000000000001592","article-title":"Salpingo-oophorectomy at the time of benign hysterectomy: a systematic review","volume":"128","author":"Evans","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.gofs.2023.03.001_bib0570","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/gme.0b013e31818888f7","article-title":"Increased cardiovascular mortality after early bilateral oophorectomy","volume":"16","author":"Rivera","year":"2009","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.gofs.2023.03.001_bib0575","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2018.10.040","article-title":"Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1\u00a0or BRCA2\u00a0mutation","volume":"152","author":"Hall","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.gofs.2023.03.001_bib0580","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejogrb.2021.08.001","article-title":"The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1\/2\u00a0mutation carriers and women with Lynch syndrome: a systematic review and meta-analysis","volume":"265","author":"Kershaw","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"10.1016\/j.gofs.2023.03.001_bib0585","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10549-018-4782-2","article-title":"Menopausal hormone therapy and the risk of breast cancer by histological type and race: a meta-analysis of randomized controlled trials and cohort studies","volume":"170","author":"Kim","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"10204","key":"10.1016\/j.gofs.2023.03.001_bib0590","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","article-title":"Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.gofs.2023.03.001_bib0595","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.critrevonc.2018.09.018","article-title":"Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1\u00a0and BRCA2\u00a0mutation carriers: a meta-analysis","volume":"132","author":"Marchetti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.gofs.2023.03.001_bib0600","first-page":"95","article-title":"Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy","volume":"148","author":"Michaelson-Cohen","year":"2021","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"8","key":"10.1016\/j.gofs.2023.03.001_bib0605","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1\u00a0mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2023.03.001_bib0610","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-term health consequences of premature or early menopause and considerations for management","volume":"18","author":"Faubion","year":"2015","journal-title":"Climacteric J Int Menopause Soc"},{"issue":"2","key":"10.1016\/j.gofs.2023.03.001_bib0615","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-017-4531-y","article-title":"Clinical implications of germline mutations in breast cancer: TP53","volume":"167","author":"Schon","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"10.1016\/j.gofs.2023.03.001_bib0620","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1245\/s10434-015-4532-1","article-title":"Bilateral risk-reduction mastectomy in BRCA1\u00a0and BRCA2\u00a0mutation carriers: a meta-analysis","volume":"22","author":"De Felice","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"15","key":"10.1016\/j.gofs.2023.03.001_bib0625","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","article-title":"Effectiveness of prophylactic surgeries in BRCA1\u00a0or BRCA2\u00a0mutation carriers: a meta-analysis and systematic review","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.gofs.2023.03.001_bib0630","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10549-019-05345-2","article-title":"Survival after bilateral risk-reducing mastectomy in healthy BRCA1\u00a0and BRCA2\u00a0mutation carriers","volume":"177","author":"Heemskerk-Gerritsen","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"10.1016\/j.gofs.2023.03.001_bib0635","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1200\/JCO.2016.69.9330","article-title":"Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study","volume":"35","author":"Rosenthal","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gofs.2023.03.001_bib0640","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ygyno.2013.06.029","article-title":"Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis","volume":"130","author":"Reade","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.gofs.2023.03.001_bib0645","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ijc.34318","article-title":"Proteomic signature for detection of high-grade ovarian cancer in germline BRCA mutation carriers","volume":"152","author":"Bahar-Shany","year":"2023","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.gofs.2023.03.001_bib0650","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.clbc.2018.09.011","article-title":"Risk reduction and survival benefit of risk-reducing salpingo-oophorectomy in hereditary breast cancer: meta-analysis and systematic review","volume":"19","author":"Xiao","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"10.1016\/j.gofs.2023.03.001_bib0655","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv033","article-title":"Breast cancer risk after salpingo-oophorectomy in healthy BRCA1\/2\u00a0mutation carriers: revisiting the evidence for risk reduction","volume":"107","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.gofs.2023.03.001_bib0330","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/jnci\/djy182","article-title":"Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk","volume":"111","author":"Terry","year":"2019","journal-title":"JNCI J Natl Cancer Inst"}],"container-title":["Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718923000533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468718923000533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:43:13Z","timestamp":1762854193000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468718923000533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2468718923000533"],"URL":"https:\/\/doi.org\/10.1016\/j.gofs.2023.03.001","relation":{},"ISSN":["2468-7189"],"issn-type":[{"type":"print","value":"2468-7189"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Femmes \u00e0 tr\u00e8s haut risque de cancer du sein\u00a0: contraception, traitement hormonal substitutif et d\u00e9pistage personnalis\u00e9","name":"articletitle","label":"Article Title"},{"value":"Gyn\u00e9cologie Obst\u00e9trique Fertilit\u00e9 & S\u00e9nologie\u00a0","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gofs.2023.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}